Holen Sie sich die Stockscreener-App
1,180.16
2.39%
-28.84
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$1,209.00
Offen:
$1194.01
24-Stunden-Volumen:
2.12M
Relative Volume:
0.72
Marktkapitalisierung:
$1.05T
Einnahmen:
$72.25B
Nettoeinkommen (Verlust:
$25.28B
KGV:
42.48
EPS:
27.781
Netto-Cashflow:
$10.37B
1W Leistung:
-0.47%
1M Leistung:
+2.40%
6M Leistung:
+13.48%
1J Leistung:
+72.43%
1-Tages-Spanne:
$1,171.20
$1,199.00
1-Wochen-Bereich:
$1,171.20
$1,240.10
52-Wochen-Spanne:
$685.15
$1,249.45
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,180.16 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
260.35 | 628.65B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
249.46 | 439.59B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
135.84 | 327.94B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
150.88 | 289.52B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Bestätigt | BofA Securities | Buy |
| 2025-12-15 | Bestätigt | Goldman | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Oppenheimer Asset Management Inc. Has $95.32 Million Stock Position in Eli Lilly and Company $LLY - marketbeat.com
Eli Lilly and Company $LLY Shares Purchased by SWS Partners - marketbeat.com
Boone County residents denied hearing on possible Eli Lilly pollutants - Goshen News
Elyxium Wealth LLC Has $7.30 Million Position in Eli Lilly and Company $LLY - marketbeat.com
Eli Lilly (LLY) Raises 2026 Revenue Guidance, Is The Stock Still A Bargain? - simplywall.st
Eli Lilly (NYSE:LLY) stock in focus as obesity treatment demand lifts guidance - kalkinemedia.com
Eli Lilly’s Weight-Loss Pill Just Went Global. Is LLY Stock Too Late to Buy? - tikr.com
Mill Capital Management LLC Boosts Stock Holdings in Eli Lilly and Company $LLY - marketbeat.com
Jennison Associates LLC Increases Position in Eli Lilly and Company $LLY - marketbeat.com
Fire Capital Management LLC Has $2.54 Million Stock Holdings in Eli Lilly and Company $LLY - marketbeat.com
This Week’s Top 5: Eli Lilly's GLP-1, Novo Nordisk and P&G - Healthcare Digital
PRIMECAP Management Co trims Eli Lilly stake by 50K - TipRanks
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) - fool.com
Eli Lilly and Company (NYSE:LLY) Trading Down 2.2%What's Next? - MarketBeat
Veeva Systems (VEEV) Could Be 24% Undervalued On Eli Lilly Global Vault CRM Rollout - simplywall.st
LLY Looks 21.8% Undervalued on GF Value™ - GuruFocus
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Eli Lilly sues companies that allegedly sold unapproved versions of new GLP-1 - BenefitsPRO
5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug - The American Journal of Managed Care
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger - Yahoo Finance
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger - The Motley Fool
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - Moomoo
Berenberg Bank Initiates Eli Lilly and Co(LLY.US) With Hold Rating, Announces Target Price $1,220 - Moomoo
Kirkland & Ellis Helps Eli Lilly Sue to Shut Down Alleged Black Market for GLP 1 - Law.com
Lilly Claims 6 Vendors Illegally Sold Obesity Drug Candidate - Law360
Eli Lilly and Company (NYSE:LLY) Stays Tied To The Metabolic Health Story - kalkinemedia.com
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race - ca.finance.yahoo.com
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity - AOL.com
Eli Lilly targets booming black market for retatrutide - STAT
Novo CEO says obesity market won't be winner-take-all battle with Lilly - Reuters
Eli Lilly Stock (LLY) Opinions on Q2 Earnings Results - Quiver Quantitative
Eli Lilly Shares Approach Record High While Retatrutide Legal Action Secures New Obesity Hope - TechStock²
Lilly veteran named director of IU Kelley School’s life sciences center - Indianapolis Business Journal
Lilly Filed Six Lawsuits Against 14,000 Listings. The Real Target Is the Payment Layer - Business Model Analyst
Lilly gains access to market that could add millions of customers - thestreet.com
Eli Lilly is a great company. Is it still a great stock? - Investing.com
Eli Lilly is a great company. Is it still a great stock? By Investing.com - Investing.com Canada
Eli Lilly cracks down on illicit weight loss drug trade with US lawsuits - Pharmaceutical Technology
Lilly Takes On Peptide Industry to Protect Buzzy Obesity Shot Retatrutide - Bloomberg.com
Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Gains as Stock Slumps - finance.yahoo.com
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide - Reuters
Eli Lilly Sues Six Companies Over Unauthorized Retatrutide Sales - RTTNews
Is Eli Lilly (NYSE:LLY) Drawing Fresh Attention As Incretin Therapies Advance? - Kalkine Media
Top Large Cap Pharma Stock: Jefferies Highlights Eli Lilly By Investing.com - Investing.com India
Top Large Cap Pharma Stock: Jefferies Highlights Eli Lilly - Investing.com
Understanding Attorney General v. Eli Lilly & Co.: What Regulated Businesses Should Know About Potentially Expanded MCPA Exposure - JD Supra
Eli Lilly Sues Six Firms Over Black-Market Sales of Unapproved Weight-Loss Drug - finance.biggo.com
What Is Keeping Eli Lilly (NYSE:LLY) in View as Inflation Data Nears? - Kalkine Media
‘Entirely Unverified Retatrutide’ Being Sold on Black Market: Lilly Sues 6 US Companies - Health and Me
Eli Lilly Stock Falls While Retatrutide Lawsuits Expand - TradingView
Lilly Targets Black-Market Retatrutide Sellers - TradingView
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.66%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):